Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report.
Membranous nephropathy (MN) post allogeneic hematopoietic stem cell transplantation (HSCT) is a rare complication with few long-term outcome data. We describe the clinical course and outcome of an adult female patient who developed MN after allogeneic HSCT for follicular non-Hodgkin's lymphoma. MN was treated with methylprednisolone as first-line therapy, then she was changed to rituximab for a relapse. After treatment with rituximab, we observed a progressive decrease of proteinuria and normalization of serum albumin. Seven months after treatment, she remains in remission. No adverse reactions to rituximab were observed throughout follow-up.